Dr. Berrin Pehlivan

Dr. Berrin Pehlivan

Verified
Consultant
  • Radiation Oncologist
MBBS, MD
Experience
26 yrs
AboutEducationAwardsSimilar doctorsFAQ

About Dr. Berrin Pehlivan

  • Dr. Berrin Pehlivan is a radiation oncologist with over 25 years of expertise.
  • Services provided by her includes treatment of cancer, radiation oncology, etc.
  • She did MBBS from Hacettepe University, Faculty of Medicine, Ankara/Turkey, in 1993.
  • She completed her MD from Hacettepe University, Faculty of Medicine, Ankara/Turkey, in 2001.
  • She holds membership in various organizations.
  • She also has several publications accredited to her name
  • Dr. Berrin Pehlivan is fluent in English, French, and Turkish.
  • VerifiedMBBS, Hacettepe University, Faculty of Medicine, Ankara/Turkey(1993)
  • VerifiedMD, Hacettepe University, Faculty of Medicine, Ankara/Turkey(2001)

Papers Published

  • Yilmaz B, Somay E, Topkan E, Pehlivan B, Selek U. Pre-chemoradiotherapy low hemoglobin levels indicate increased osteoradionecrosis risk in locally advanced nasopharyngeal cancer patients. Eur Arch Otorhinolaryngol. 2023 Feb 7.
+ Read More
  • Somay E, Yilmaz B, Topkan E, Kucuk A, Pehlivan B, Selek U. Initial neutrophil-to-lymphocyte ratio predicts radiation-induced trismus in parotid gland cancer. Oral Dis.2022 Nov 8.
  • Somay E, Yilmaz B, Topkan E, Kucuk A, Haksoyler V, Pehlivan B, Selek U, Araz K. Hemoglobin-to-platelet ratio in predicting the incidence of trismus after concurrent chemoradiotherapy. Oral Dis 2022 Aug 29.
  • Topkan E, Selek U, Kucuk A, Pehlivan Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. J Inflamm Res. 2022 Sep 18;15:5413-5423.
  • Topkan E, Selek U, Haksoyler V, Kucuk A, Durankus NK, Sezen D, Bolukbasi Y, Pehlivan B. Postchemoradiotherapy Neutrophil-to-Lymphocyte Ratio Predicts Distant Metastasis and Survival Results in Locally Advanced Pancreatic Cancers. Int J Clin Pract. 2022 Jan 31;2022:7473649.
  • Yalcin K, Pehlivan B, Celen S, Bas EG, Kabakci C, Pashayev D, Daloglu H, Zhumatayev S, Uygun V, Karasu GT, Hazar V, Yesilipek A. Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL. J Pediatr Hematol Oncol2021 Mar 31.
  • Kucuk A, Topkan E, Selek U, Haksoyler V, Mertsoylu H, Besen AA, Pehlivan B. High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients. Ther Clin Risk Manag. 2022 Apr 14;18:421-428.
  • Topkan E, Selek U, Küçük A, Haksöyler V, Özdemir Y, Sezen D, Mertsoylu H, Besen AA, Bölükbaşı Y, Özyılkan O, Pehlivan B. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis. J Oncol 2021 Jan 23;2021.
  • Küçük A, Ozkan EE, Öztep SE, Mertsoyle H, Pehlivan B, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol 2020 Dec 16.
  • Topkan E, Besen AA, Mertsoylu H, Kucuk A, Pehlivan B, Selek U. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. Int J Inflam. 2020 Jun 8;2020.
  • Topkan E, Mertsoylu H, Kucuk A, Besen AA, Sezer A, Sezen D, Bolukbasi Y, Selek U, Pehlivan B. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. Gastroenterol Res Pract. 2020 Jul 30;2020.
  • Topkan E, Ozdemir Y, Guler OC, Kucuk A, Besen AA, Mertsoylu H, Sezen D, Akdemir EY, Sezer A, Bolukbasi Y, Pehlivan B, Selek U.  Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study. J Oncol. 2020 Sep 4;2020.
  • Topkan E, Kucuk A, Ozdemir Y, Mertsoylu H, Besen AA, Sezen D, Bolukbasi Y, Pehlivan B, Selek U. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol. J Immunol Res. 2020 Nov 14;2020.
  • Kucuk A, Ozkan EE, Eskici Oztep S, Mertsoylu H, Pehlivan B, Selek U, Topkan E. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. J Oncol2020 Dec 16;2020.
  • Topkan E, Besen AA, Ozdemir Y, Kucuk A, Mertsoylu H, Pehlivan B and Selek U. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Post-neurosurgical Radiotherapy plus Concurrent and Adjuvant Temozolomide. Mediators Inflamm. 2020 23;2020.
  • Kucuk A, Topkan E, İkiz ED, Durankuş N, Senyurek S, Aydemir EY, Sezen D, Bolukbaşı Y, Selek U, Pehlivan B. Combination of stereotactic radiosurgery with immunotherapy: is it a new treatemnt option for brain metastases? Int Res J Oncol, 2020.
  • Topkan E, Küçük A, Şenyürek S, Sezen D, Durankuş NK, Aydemir EY, İkiz ED, Bölükbaşı Y, Pehlivan B ve Selek U. Preoperative radiosurgery in management of brain metastases. J Cancer Tumor Int, 10(1):1-11, 2020.
  • Topkan E, Küçük A, Sezen D, Senyürek S, Aydemir EY, Durankuş N, İkiz ED, Bolükbaşı Y, Pehlivan B ve Selek U. Common prognostic scoring system for patients presenting with brain metastases. Clin Oncol Res, 2020.
  • Pehlivan B, Topkan E, Küçük A, Okumuş A, Sezen D, Bölükbaşı Y, Selek U. Stereotactic radiosurgery and targeted therapies for brain metastases from solid cancers. JAMMR,ISSN:2456-8899.
  • Topkan E, Küçük A, Durankuş NK, Şenyürek Ş, Akdemir EY, Sezen D, İkiz ED, Bölükbaşı Y, Pehlivan B, Selek U. Radiosurgical management of brainstem metastasis. Int Res J Oncol, 2020 3(1):37-46.
  • Sağlam Y, Bölükbaşı Y, Atasoy Aİ, Karaköse F, Alpan V, Selek U, Küçük A, Pehlivan B, Topkan E. Quality assurance in stereotactic radiosurgery and stereotactic body radiotherapy. Advances in Research 21 (7), 22-33.
  • Topkan E, Küçük A, Şenyürek Ş, Sezen D, Durankuş NK, Akdemir EY, Sağlam Y, Bölükbaşı Y, Pehlivan B, Selek U. Radiosurgery techniques for brain metastases. JCTI 2020; 10, 1-14.
  • Bölükbaşı Y, Selek U, Sezen D, Durankuş NK, Akdemir EY, Şenyürek Ş, Küçük A, Pehlivan B, Topkan E. Tumor cavity stereotactic radiosurgery for resected brain metastases. JCTI 2020, 10(2):15-30.
  • Pehlivan B, Sengul K, Yesil A, Nalbant N, Ozturk O, Ozdemir Y, Topkan E. Dosimetric comparison of lung-sparing radiation therapy between volumetric arc therapy and helical tomotherapy for unresectable malignant pleural mesothelioma. BioMed Res Int, 2019.
  • Pehlivan B, Kucuk A, Mertsoylu H, Topkan E. Current management of brainstem gliomas. Int. J.Adv. Res. 7(9), 2019.
  • Topkan E, Pehlivan B. Radiation-induced abscopal effects on cardiovascular system. IndJMedResPharmSci, 6(9), 2019.
  • Golusinski P, Di Maio P, Pehlivan B, Colley S, Nankivell P, Kong A, Hartley A, Mehanna H. Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncol. 2019 Jan;88:145-152.
  • Topkan E, Selek U, Ozdemir Y, Besen AA, Guler OC, Yildirim BA, Mertsoylu H, Findikcioğlu A, Ozyılkan O, Pehlivan B. Risk factors for .fatal pulmonary hemorrahage following concurrent chemoradiotherapy in stage 3B/C squamous-cell lung carcinoma patients. J Oncol 2018 Nov 1;2018.
  • Topkan E, Yildirim BA, Guler OC, Parlak C, Pehlivan B, Selek U. Safety and palliative efficacy of single-dose-8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):774-80.
  • Duman E, Cecen Y, Sındır B, Ozdemir B, Yıldırım M, Cecen S, Pehlivan B, Yavuz MN. Dosimetric evaluation of Adaptive Therapy in non-small lung cancer patients undergoing palliative thoracic Radiotherapy. Int J Hematol Oncol. 2015, 25:178-185.
  • Mirimanoff RO, Ozsahin M, Thariat J, Ozyar E, Schick, Pehlivan B, Krengli M, Pellanda AF, Vess H. Cai L, Scandolaro L, Belacemi Y, Villa S, Igdem S, Lutsyk M, Miller RC. History of rare cancer network and past research. Rare Tumors. 2014 Aug 6;6(3):5462.
  • Sarıca FB, Cekinmez M, Tufan K, Sen O, Onal HC, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Altinors B. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and efeectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. Asian J Neurosurg. 2012 Oct;7(4):181-90.
  • Topkan E. Parlak C, Topuk S, Pehlivan B. Influence on oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. BMC Cancer 2012 Oct 31;12:502.
  • Pehlivan B, Ares C, Lomax T, Stadelmann O, Goitein G, Timmermann B, Schneider RA, Hug EB.: Temporal lobe toxicity analyasis after proton radiation therapy for skull base tumors. Int J Radiat Oncol Biol Phys 2012 Aug 1;83(5):1432-40.
  • Topkan E, Parlak C, Kotek A, Yuksel O, Cengiz M, Ozsahin M, Pehlivan B. Impact of prophylactic cranial irradiation timing on brain relapse rates in patients with stage IIIB non-small-cell lung carcinoma treated with two different chemoradiotherapy regimens. Int J Radiat Oncol Biol Phys 2012 July 15;83(4):1264-71.
  • Pehlivan B, Onal C, Yavuz M.: Retinoblastoma Tedavisinde Eksternal Radyoterapinin Rolü ve Radyoterapi Seçenekleri. Int J. Hematol Oncol. 2012, 22(2):1-9.
  • Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 2011 10,11:123.
  • Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 2012; 35(3):284-9.
  • Sarıca F, Tufan K, Çekinmez M, Şen O, Onal HC, Mertsoylu H, Pehlivan B, Erdoğan B, Altınors MN. Effectiveness of temozolomide treatment used at thesame time with radiotherapyand adjuvant temozolomid: concomitant therapy of glioblastoma multiforme:         multivariate analysis and other prognostic factors. J Neurosurg Sci. 2010; 54(1): 7-19.
  • Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, Matzinger O, Zouhair A.: Outcome and prognostıc factors ın olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):992-7.
  • Yavuz MN, Topkan E, Yavuz AA, Aydin M, Onal C, Reyhan M, Kotek A, Pehlivan B, Yapar AF.: FDG-PET/CT Imaging-based taget volume delineation for preoperative conformal radiotherapy for rectal carcinoma. Int J Hematol Oncol 2010, 20(2):067-074.
  • Pehlivan B, Topkan E, Onal C, Nursal GN, Yüksel O, Yavuz M, Yavuz A.: Comparison of CT and integrated PET-CT based radiation therapy planning in malign plevral mesothelioma patients. Radiat Oncol. 2009, 4:35.
  • Pehlivan B, Luthi F, Matzinger O, Betz M, Dragusanu D, Bulling S, Bron L, Pasche P, Seelentag W, Mirimanoff RO, Zouhair A, Ozsahin M.: Feasibility and efficacity of accelerated weekly concomitant boost postopeartive radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer. Ann Surg Oncol. 2009, 16:1337-1343.
  • Pehlivan B, Pichenot C, Casting M, Auperin A, Arriagada R, Bourhis J.: Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients. Acta Oncol. 2009, 48(3):440-5.
  • Pehlivan B, Zouhair A, Luthi F, Bron L, Pasche P, Dragusanu D, Azria D, Matzinger O, Mirimanoff RO, Ozsahin M.: Decrease in hemoglobin levels following surgery influences the outcome in head and neck cancer patients treated with accelerated postoperative radiotherapy. Ann Surg Oncol. 2009, 16:1331-1336.
  • Onal C, Arslan G, Topkan E, Pehlivan B, Yavuz M, Oymak E, Yavuz A.: Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer: target volume coverage and organs at risk doses. J Exp Clin Cancer Res. 2009 Jul 1;28:95.
  • Onal C, Pehlivan B, Bal N, Topkan E, Kilinc F, Topuk S. : Sarcomatoid Carcinoma of the Urinary Bladder Treated with Adjuvant Radiotherapy: A Case Report. Clinical Medicine: Case Reports 2009:2 39-42.
  • Onal C, Yuksel O, Topkan E, Pehlivan B. : Bilateral glomus tumor treated with PET-CT based conformal radiotherapy: case report. Cases Journal 2009, 2:8402.
  • Atahan IL, Yıldız F, Ozyar E, Pehlivan B, Genç M, Köse M, Tulunay G, Ayhan A, Yuce K, Güler N, Kucukali T.: Radiotherapy in the adjuvant setting of cervical carcinoma: treatment, results, and prognostic factors. Int J Gynecol Cancer 2007, 17 (4): 813-820.
  • Garcia R, Bourhis J, Pehlivan B, Pichenot C, Alfonsi M.: Intensity modulated radiotherapy for cancers of the upper aerodigestive tract. Cancer Radiother 2007, 11(6-7):353-7.
  • Pehlivan B, Topkan E, Yavuz A.: Protonterapy in clinical use. Ege Tıp Dergisi, 50(1):1-6, 2011

Send Your Enquiry

Fill in your details and our medical experts will contact you within 24 hours.

By submitting I agree to the Terms of Use and Privacy Policy of Vaidam Health.

Want to consult the doctor?

Don't Ignore Your Health!

Other Top Radiation Oncologist In Istanbul

Dr. Enis Ozyar

Dr. Enis Ozyar

Radiation Oncologist
Acibadem Hospitals Group · Istanbul
31+ years of experience
Chat IconChat
Dr.Ilan Gil Ron

Dr.Ilan Gil Ron

Radiation Oncologist
Medical Park Group, Istanbul · Istanbul
37+ years of experience
Chat IconChat
Dr Asli Saran Ikizler

Dr Asli Saran Ikizler

Radiation Oncologist
Acibadem Hospitals Group · Istanbul
36+ years of experience
Chat IconChat
Dr. Zoran Trajkovski

Dr. Zoran Trajkovski

Radiation Oncologist
Acibadem Hospitals Group · Istanbul
39+ years of experience
Chat IconChat

FAQ's About Dr. Berrin Pehlivan

What is the specialty of Dr. Berrin Pehlivan?

Dr. Berrin Pehlivan specialty is Radiation Oncologist

What is the experience of Dr. Berrin Pehlivan?

Dr. Berrin Pehlivan is Radiation Oncologist with 26 years of experience.

Our Network

500+

Top Hospitals

10,000+

Doctors

50+

Cities

10+

Countries

Need Assistance?Chat